Adicet Bio completes last patient visit for planned prula-cel analysis
Adicet Bio (ACET) said it has completed the last patient visit for the planned analysis of its prula-cel (formerly ADI-001) study in systemic lupus erythematosus with or without lupus nephritis, and provided a corporate update.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.